Citigroup Upgrades Genzyme (GENZ) to Buy
GENZ Hot Sheet
Rating Summary:1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Citigroup upgrades Genzyme (Nasdaq: GENZ) from Hold to Buy, but trims their price target from $64 to $63.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- UPDATE: Patriot Coal (PCX) Continues to Work with Lenders to Strengthen Financing, Hired Blackstone
Create E-mail Alert Related Categories
Trader Talk, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
